핵산 치료제 위탁생산 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Nucleic Acid Therapeutics Contract Manufacturing Market Summary

The global nucleic acid therapeutics contract manufacturing market size was estimated at USD 9.85 billion in 2024 and is projected to reach USD 33.84 billion by 2033, growing at a CAGR of 15.14% from 2025 to 2033. The market is witnessing growth driven by growing biopharmaceutical outsourcing trends, rising demand for mRNA and gene therapies, and technological advancements in manufacturing.

Increasing regulatory support and government incentives are among the other factors driving market growth. In the global market, shifting trends towards outsourcing activities by biopharmaceutical companies to contract manufacturers are expected to drive market growth. This outsourcing activity reduces operational costs, accelerates time-to-market, and utilizes specialized expertise in nucleic acid production. According to an article published in July 2025, 82.6% of cell and gene therapy (CGT) companies outsource at least part of their biologics manufacturing, marking record-high levels of reliance on external contract manufacturing services.

In addition, outsourcing activities is also driven by the high complexity of mRNA, plasmid DNA, and oligonucleotide therapeutics, which require GMP-certified facilities, skilled personnel, and advanced technologies. Thus, contract manufacturers are witnessing an increasing requirement for integrated services, including process development, analytical testing, and commercial-scale manufacturing. In addition, outsourcing enables pharmaceutical firms to concentrate on research and development, ensuring that regulatory compliance and quality standards are met.

Global Nucleic Acid Therapeutics Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid therapeutics contract manufacturing market report based on type, service, application, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Gene Therapy
  • Plasmid DNA (pDNA)
  • Viral Vectors
  • Non-viral Gene Delivery Systems
  • Others
• RNA-based Therapies
  • Messenger RNA (mRNA)
  • Small Interfering RNA (siRNA)
  • Antisense Oligonucleotides (ASO)
  • Other
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Process Development and Optimization
• GMP Manufacturing
• Analytical and Quality Control Service
• Fill-Finish Contract Manufacturing
• Regulatory Support
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Rare Diseases
• Genetic Disorders
• Infectious Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Biopharmaceutical Companies
• Medium Biopharmaceutical Companies
• Small Biopharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Service
  • 1.2.3. Application
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Nucleic Acid Therapeutics Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Demand for Cell and Gene Therapies
    • 3.2.1.2. Increased Outsourcing by Biopharma Companies
    • 3.2.1.3. Technological Advancements in Manufacturing Platforms
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Production Complexity and Cost
    • 3.2.2.2. Limited Skilled Workforce and Technical Expertise
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Nucleic Acid Therapeutics Contract Manufacturing Market: Type Estimates & Trend Analysis

• 4.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Segment Dashboard
• 4.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Movement Analysis
• 4.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Gene Therapy
  • 4.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Plasmid DNA (pDNA)
    • 4.4.2.1. Plasmid DNA (pDNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Viral Vectors
    • 4.4.3.1. Viral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Non-viral Gene Delivery Systems
    • 4.4.4.1. Non-viral Gene Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. RNA-based Therapies
  • 4.5.1. RNA-based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Messenger RNA (mRNA)
    • 4.5.2.1. Messenger RNA (mRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Small Interfering RNA (siRNA)
    • 4.5.3.1. Small Interfering RNA (siRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Antisense Oligonucleotides (ASO)
    • 4.5.4.1. Antisense Oligonucleotides (ASO) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Nucleic Acid Therapeutics Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Segment Dashboard
• 5.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Movement Analysis
• 5.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Process Development and Optimization
  • 5.4.1. Process Development and Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. GMP Manufacturing
  • 5.5.1. GMP Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Analytical and Quality Control Service
  • 5.6.1. Analytical and Quality Control Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Fill-Finish Contract Manufacturing
  • 5.7.1. Fill-Finish Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Regulatory Support
  • 5.8.1. Regulatory Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Nucleic Acid Therapeutics Contract Manufacturing Market: Application Estimates & Trend Analysis

• 6.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Segment Dashboard
• 6.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Movement Analysis
• 6.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Rare Diseases
  • 6.5.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Genetic Disorders
  • 6.6.1. Genetic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Infectious Diseases
  • 6.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Nucleic Acid Therapeutics Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 7.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Segment Dashboard
• 7.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Movement Analysis
• 7.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Large Biopharmaceutical Companies
  • 7.4.1. Large Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Medium Biopharmaceutical Companies
  • 7.5.1. Medium Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Small Biopharmaceutical Companies
  • 7.6.1. Small Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Nucleic Acid Therapeutics Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Lonza Group
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Thermo Fisher Scientific
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Catalent Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. WuXi AppTec
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. AGC Biologics
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Agilent Technologies
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Ajinomoto Bio-Pharma Services
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. BioSpring GmbH
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Bachem Holding AG
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. CordenPharma International GmbH
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Danaher Corporation
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Eurofins Scientific
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Avecia (Nitto Denko / Avecia)
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. BioCina Pty Ltd.
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Kaneka Corporation
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives